Squarepoint
EWTX icon

Squarepoint’s Edgewise Therapeutics EWTX Stock Holding History

Squarepoint’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,276
Closed -$1.22M – 4441
2025
Q3 		$1.22M Buy
+75,276
New +$1.07M ﹤0.01% 2510
2025
Q2 		– Sell
-45,756
Closed -$1.01M – 4649
2025
Q1 		$1.01M Buy
45,756
+19,398
+74% +$509K ﹤0.01% 2650
2024
Q4 		$704K Buy
26,358
+9,729
+59% +$310K ﹤0.01% 3408
2024
Q3 		$444K Sell
16,629
-35,912
-68% -$714K ﹤0.01% 3192
2024
Q2 		$946K Buy
52,541
+27,687
+111% +$483K ﹤0.01% 2594
2024
Q1 		$453K Buy
24,854
+13,244
+114% +$211K ﹤0.01% 3117
2023
Q4 		$127K Buy
+11,610
New +$81.5K ﹤0.01% 3706
2022
Q1 		– Sell
-12,197
Closed -$186K – 3037
2021
Q4 		$186K Buy
+12,197
New +$219K ﹤0.01% 2735
2021
Q2 		– Sell
-20,185
Closed -$656K – 3361
2021
Q1 		$656K Buy
+20,185
New +$655K ﹤0.01% 1824

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Squarepoint's EWTX Position: Q4 2025 in Review

Squarepoint sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 75,276 shares — an estimated $1.22M sold.

Squarepoint first reported a position in EWTX in Q1 2021 and held it in 9 quarters. The position peaked at $1.22M in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Squarepoint reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 75,276 Edgewise Therapeutics shares in Q4 2025, an estimated $1.22M.
  • Squarepoint first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 9 quarters.
  • Squarepoint's Edgewise Therapeutics position peaked at $1.22M in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.